CardiacWire

JULY 28, 2024

Edwards Lifesciences is going all-in on structural heart and heart failure, acquiring aortic valve-maker JenaValve Technology and implantable heart failure monitor company Endotronix for $1.2B and up to $445M in milestone payments.

Heart Failure 59

Heart Failure Aortic TAVR Critical Care 59

DAIC

MARCH 5, 2024

Andrea Fletcher , Chief Digital Strategy Officer and Director of the Digital Service at Centers for Medicare and Medicaid Services ( CMS ) will present, “ Teaching the Elephant to Dance: Digital Transformation in the United States ” on March 13 in an afternoon education session.

CMS 52

CMS COVID-19 Medicare Education 52

DAIC

JUNE 4, 2024

In January 2024, the Centers for Medicare and Medicaid Services (CMS) began requiring health care organizations to screen for five social factors: Food insecurity Interpersonal safety Housing insecurity Transportation Utilities The purpose of these screenings is to encourage engagement of community-based organizations with resources to address SDOH.

Strokes 115

Strokes Stroke Innovation Research 115

GEMMS

MARCH 7, 2024

In late 2023, CMS released the 2024 Medicare Physician Fee Schedule (MPFS) Final Rule, ushering in key policy changes for the Quality Payment Program (QPP). EHR technology certified to the 2015 Cures Update must be in place by October 3, 2023. You pick the quality measures that best fit your practice.

Medicare 52

Medicare CMS Document Technology 52

GEMMS

JANUARY 2, 2024

This technology is essential for any practice looking to maximize patient care and save money. Key features include: Compliance Under Appropriate Use Criteria (AUC) – GEMMS ONE meets CMS standards and requirements by including an AUC orders module, part of its integrated system.

Document 52

Document Patient Care Private Practice Reimbursement 52

DAIC

MARCH 13, 2024

CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage.

CMS 111

CMS Heart Failure Reimbursement Quality of Life 111

DAIC

DECEMBER 8, 2023

The DRAIN-HF study will evaluate the Aortix percutaneous mechanical circulatory support (pMCS) technology in patients with acute decompensated heart failure (ADHF) who are unresponsive to standard medical therapy. The company recently announced it has received CMS approval for Medicare coverage during the DRAIN-HF pivotal trial.

Technology 113

Technology Heart Failure Heart Transplant Transplant 113

DAIC

MARCH 28, 2025

v As cardiovascular disease (CVD) continues to rise globally, vi the need for advanced diagnostic technologies like cardiac CT angiography (CCTA) becomes increasingly critical. vii Similarly, recent increases in Medicare reimbursement rates for CCTA are a positive step towards making this technology more accessible.

Technology 59

Technology Coronary Artery Disease Atrial Fibrillation Medicare 59

DAIC

MARCH 7, 2024

Computed Tomography (CT) continues to be a rapidly evolving technology with many new advancements, as displayed and discussed at the Radiological Society of North America109th Scientific Assembly and Annual Meeting (RSNA23). As a whole, the computed tomography market size in the US in 2024 is estimated to be $2.38

Technology 111

Technology Document Cardiovascular Imaging Cancer 111

DAIC

MARCH 14, 2024

AMA is hearing reports that despite CMS instructions, some MACs are still requiring a waiver to accept paper claims. CMS should ensure that MACs allow paper claims without waivers. Automatically apply hardship exemptions for CMS-impacted programs. Encourage the health information technology community to postpone user fees.

CMS 101

CMS Medicare Medicaid Technology 101

DAIC

JULY 29, 2024

Edwards has entered into an agreement to acquire JenaValve Technology , a pioneer in the transcatheter treatment of aortic regurgitation (AR), a deadly disease that impacts a significant and growing population and is largely untreated today. A CMS national coverage determination is expected in early 2025.

Innovation 105

Innovation Aortic valve Aortic CMS 105

DAIC

MARCH 7, 2024

The data was presented today by Amish Raval , MD, Director of Clinical Cardiovascular Research and Professor of Medicine at the University of Wisconsin-Madison at the Technology and Heart Failure Therapeutics (THT) 2024 annual meeting. The CardiAMP HF II trial is expected to similarly secure CMS reimbursement.

Heart Failure 105

Heart Failure Biomarkers Reimbursement CMS 105

DAIC

JANUARY 14, 2025

13, 2025 Medtronic plc recently announced that the Centers for Medicare & Medicaid Services (CMS) is opening a national coverage analysis (NCA) on renal denervation, a process that will allow the agency to review and develop a national Medicare coverage policy for renal denervation procedures for patients with hypertension.

CMS 52

CMS Medicare Blood Pressure Medicaid 52

DAIC

JANUARY 13, 2025

Additionally, the company announced that the Centers for Medicare & Medicaid Services (CMS) has granted Category B approval for the investigational device exemption (IDE) study, ensuring Medicare coverage for the device, related and routine items, and services for the ELITE-BTK trial. Commenting on the announcements, Christopher M.

Peripheral Arterial Disease 52

Peripheral Arterial Disease CMS Medicare Medicaid 52

Cardiometabolic Health Congress

DECEMBER 9, 2024

In addition, barriers such as the cost of advanced technology, insurance coverage, and concerns over the usability of CGM devices have historically made it difficult for many patients to access these tools. As insurance coverage improves , especially through programs like CMS, more patients can access this life-changing technology.

Diabetes 52

Diabetes Technology Education CMS 52

DAIC

JANUARY 27, 2025

13, 2025 Medtronic recentlyannounced that the Centers for Medicare & Medicaid Services (CMS) is opening a national coverage analysis (NCA) on renal denervation, a process that will allow the agency to review and develop a national Medicare coverage policy for renal denervation procedures for patients with hypertension.

CMS 52

CMS Blood Pressure Medicare Hypertension 52